Funding Announcement: Drs. Mark Miedel and Alejandro Soto-Gutierrez have received an RO1 from the NIDDK to implement a QSP platform to predict and test drugs for metabolic-associated steatotic liver disease genetic variants in an iPSC-cell based human biomimetic liver microphysiology system.